Research programme: rheumatoid arthritis gene therapies - Biogen Idec

Drug Profile

Research programme: rheumatoid arthritis gene therapies - Biogen Idec

Alternative Names: Rheumatoid arthritis gene therapies research programme - Biogen Idec

Latest Information Update: 24 Feb 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Biogen Idec
  • Class Gene therapies
  • Mechanism of Action Cytokine inhibitors; Interleukin 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Rheumatoid arthritis

Most Recent Events

  • 29 Oct 2004 Preclinical trials in Rheumatoid arthritis in Netherlands (Intra-articular)
  • 29 Oct 2004 Preclinical trials in Rheumatoid arthritis in USA (Intra-articular)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top